Evidence map›Paper›PMID 29664936›Full record

ArticlePloS one2018

Olfactory dysfunction as a prognostic marker for disability progression in Multiple Sclerosis: An olfactory event related potential study.

Rosella Ciurleo, Lilla Bonanno, Simona De Salvo, Laura Romeo, Carmela Rifici, Edoardo Sessa, Giangaetano D'Aleo, Margherita Russo, Placido Bramanti, Silvia Marino and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. International consensus statement on allergy and rhinology: Olfaction.International forum of allergy & rhinology · 2022
    Review
  4. [Predictors of posttreatment olfactory improvement in patients with postviral olfactory dysfunction].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2021
    Article
  5. Prognostic value of olfactory evoked potentials in patients with post-infectious olfactory dysfunction.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2021
    Article
  6. Article
  7. Th17 lymphocytes drive vascular and neuronal deficits in a mouse model of postinfectious autoimmune encephalitis.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Rosella CiurleoIRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy.ORCID 0000-0003-0709-5914
Lilla BonannoIRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy.
Simona De SalvoIRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy.
Laura RomeoIRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy.
Carmela RificiIRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy.
Edoardo SessaIRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy.
Giangaetano D'AleoIRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy.
Margherita RussoIRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy.
Placido BramantiIRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy.
Silvia MarinoIRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy.
Fabrizia CaminitiIRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy.
Centro Neurolesi Bonino Pulejo · ITUniversity of Messina · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is a chronic inflammatory disease and one of the leading causes of disability in young adults. Functional markers able to predict MS progression are still lacking. It is recognized that olfactory dysfunction may be an early symptom in MS. The aim of this study was to investigate whether alterations in olfactory event-related potentials could play a prognostic role in MS. Thirty patients affected by MS relapsing-remitting underwent an olfactory potential examination (T0). Three years after baseline (T1), 28 of 30 patients were clinically evaluated by expanded disability status scale. In addition, the number of Disease Modifying Therapies (DMTs) and the total number of relapses occurred in the last 3 years were collected. At T1, we observed a negative correlation between presence/absence of olfactory potentials and expanded disability status scale scores (rpb = -0.48; p = 0.009). A significant trend for a negative correlation between presence/absence of olfactory potentials and disease duration (rpb = -0.36; p = 0.06) and total number of relapses (rpb = -0.34; p = 0.08) was found. Only patients with olfactory potential absence showed a significant trend in the difference of the disability status scale (p = 0.06) between T0 and T1. In the sub-group of patients with reduced olfactory potential amplitude, we detected a trend for a negative correlation between the disability status scale and the amplitude of N1-P2 components more marked at T1 (r = -0.52; p = 0.06) than T0 (r = -0.47; p = 0.09). This is the first study that evaluated the prognostic role of olfactory event-related potentials in MS. Our results highlighted that olfactory alterations of MS patients were related to disability progression and, to a lesser extent, disease activity. The analysis of olfactory potential parameters confirmed the involvement in olfactory network damage of inflammatory and/or neurodegeneration processes which could predict the progressive course of the disease.

Indexed as

Disability EvaluationAdultDisease ProgressionEvoked PotentialsFemaleHumansMaleMiddle AgedMultiple SclerosisOlfaction DisordersPersons with DisabilitiesPrognosisReproducibility of Results

Identifiers

PMID29664936
PMCPMC5903665
OpenAlexW2799528767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.